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A b s t r a c t
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive 
disease. Pharmacological treatment can only slow its progression. However, 
lung transplantation (LTx) is the only treatment for patients with its end-
stage form. This study analysed the long-term results of the qualification 
process of patients with IPF recruited for LTx in a single centre.
Material and methods: Retrospective analysis of 84 patients (56 patients 
who died while on the waiting list and 28 patients who underwent LTx) with 
end-stage IPF who were qualified for LTx between 2006 and 2017 at the 
Silesian Centre for Heart Diseases (Zabrze, Poland).
Results: Cox proportional hazard analysis showed that the only parameter 
was 6-minute walk test (6MWT) distance, which statistically significantly im-
pacted the probability of receiving a graft (parameter assessment, 0.00523; 
p = 0.006; 95% confidence interval (CI): 0.0015–0.009; hazard ratio (HR) = 
1.005) as well as that of death while on the waiting list (parameter assess-
ment, –0.0054; p = 0.003; 95% CI: –0.009– (–0.0017); HR =  0.995). Patients 
with a 253–350-m 6MWT distance had 3 times greater risk of dying while 
on the waiting list than those who walked more than 350 m. Other factors, 
such as height, sex, and blood group, also influenced the outcome.
Conclusions: The 6-minute walk test distance is an independent predictor of 
mortality on the lung transplant waiting list. Blood type and height also play 
a significant role in becoming a lung recipient. 
Key words: idiopathic pulmonary fibrosis, interstitial lung diseases, lung 
transplantation, qualification, mortality.
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common form of chron-
ic, progressive interstitial lung disease (ILD) [1]. Characterized by growth 
of fibrotic tissue in the parenchyma of the lungs, IPF is associated with 
high morbidity and poor prognosis [2]. Patients become less and less 
self-reliant, finally being dependable on other people or home health ser-
vices [3]. The mean survival time for patients with IPF ranges from 3 to 
5 years. In Europe, the incidence of IPF was 3–9 cases per 100,000 people 
in 2017 and is increasing [4]. The radiographic findings of subpleural re-
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ticulation, honeycombing, and bronchiectasis are 
typical for IPF [5]. Its progression is characterized 
by lowered diffusion capacity for carbon monox-
ide (DLCO), forced vital capacity (FVC), and total 
lung capacity (TLC) in pulmonary function tests 
[5]. Although the pathogenesis of IPF has been 
studied for more than 20 years, it still remains un-
clear [6, 7]. Risk factors that have been associat-
ed with the outbreak of IPF are cigarette smoking 
and exposure to wood, metal, stone, and organic 
dust [7]. The IPF is diagnosed only after exclud-
ing other ILDs [8]. Clinical presentation of IPF is 
not distinctive among ILDs [9]. Pirfenidone (antifi-
brotic drugs) and nintedanib (multityrosine kinase 
inhibitor) can slow the progression of IPF, so they 
are used in the treatment of IPF [1]. However, the 
only treatment that is proven to help the patients 
is lung transplantation (LTx) [10]. During the qual-
ification process, in accordance with the Interna-
tional Society of Heart and Lung Transplantation 
(ISHLT) guidelines, the following clinical findings 
are taken into consideration:
•	 Decline in FVC ≥ 10% during 6 months of fol-
low-up (note: a 5% decline is associated with 
a poorer prognosis and may warrant listing);
•	 Decline in DLCO ≥ 15% during 6 months of fol-
low-up;
•	 Oxygen desaturation to < 88%, a 6-minute walk 
test (6MWT) distance < 250 m, or a > 50 m de-
cline in 6MWT distance over a 6-month period;
•	 Pulmonary hypertension on right heart cathe-
terization or 2-dimensional echocardiography;
•	 Hospitalization because of respiratory failure, 
pneumothorax or acute exacerbation [11].
The first successful LTx with long-term survival 
was performed in 1983 at the University of To-
ronto. The recipient was a patient with IPF. Since 
then, LTx has become an established method of 
treatment for patients with end-stage IPF [10]. 
Systems of lung allocation vary across different 
lung transplant programmes. It is worth remem-
bering that each allocation system favours differ-
ent potential recipients. 
The aim of this study was to analyse the long-
term results of the qualification process of pa-
tients with IPF recruited for LTx in a single centre. 
Material and methods
Study population
This retrospective cohort study analysed clini-
cal records of 84 patients with IPF. Its population 
comprised patients with the end stage of this lung 
disease who were qualified to undergo LTx accord-
ing to the ISHLT guidelines for potential recipients 
(30 women, 54 men; median age at qualification, 
51.11 years; range: 18–65 years). The study group 
included 56 (63.53%) patients who died while on 
the waiting list (25 women, 31 men; median age 
at qualification: 52.37 years; range: 18–65 years) 
and 28 patients who underwent LTx (32.94%) 
(5 women, 23 men; median age: 48.83 years; 
range: 25–60 years) between 2006 and 2017 in the 
Silesian Centre for Heart Disease (Zabrze, Poland). 
Qualified patients with unknown end-points (nei-
ther undergoing LTx nor dying while on the nation-
al LTx waiting list) were excluded from the study.
Data collection
Data regarding the qualification for LTx were 
collected from the medical records and potential 
recipient questionnaires. The following basic char-
acteristics were analysed: age (years), sex, height 
(cm), weight (kg), body mass index (kg/cm2), 
and time spent on the waiting list (days). During 
the qualification process, kidney function (serum 
creatinine (mg/dl), estimated glomerular filtration 
rate (ml/min–1/1.73 m2)), liver function (serum bil-
irubin (mg/dl), aspartate transaminase (UI/l), ala-
nine transaminase (UI/l)), lipid profile, full blood 
count and N-terminal prohormone of brain na-
triuretic peptide (NT-proBNP) levels (pg/ml) were 
evaluated in laboratory tests. Pulmonary function 
tests, such as spirometry (forced expiratory volume 
in 1st s (FEV1%), actual FEV1 (l), and forced vital ca-
pacity (FVC%)), as well as arterial blood gas assess-
ment, were performed. Further, 6MWT distance 
(m), Borg’s scale, and oxygen saturation (SpO2 (%)) 
were analysed. Cardiac evaluation included echo-
cardiography (left ventricle ejection fraction (%), 
right ventricular systolic pressure (mm Hg), tricus-
pid annular plane systolic excursion (mm), and ac-
celeration time (ms)) and right heart catheteriza-
tion (mean artery pulmonary pressure (mm Hg)). 
The following lung plethysmography parameters 
were also assessed: predicted total lung capacity 
(TLC) (l) and residual volume (RV) (%).
Statistical analysis
Data were expressed as mean ± standard de-
viation. The Mann-Whitney U-test, c2 test with 
Yates’ correction, and maximum likelihood chi-
squared test were used, as appropriate. Statisti-
ca 10.0 software (StatSoft, Inc., Tulsa, OK, USA) 
was used for statistical analysis. All findings with 
p < 0.05 were considered statistically significant. 
The results in certain tables were presented as 
hazard ratios (HRs) with 95% confidence intervals 
(CIs). Cox proportional hazard analysis was used 
for evaluation of the effect of continuous and di-
chotomous data on the incidence of death. Con-
sidering their collinearity, statistically significant 
variables from the single factor analysis (p < 0.05) 
were included in the multiple factor analysis using 
Cox proportional hazard analysis.
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Results
Statistically significant findings regarding pa-
tients’ results during qualification for LTx are pre-
sented in Table I. Significant differences between 
deceased patients and those who underwent LTx 
were observed in the following parameters: per-
centage of female patients, actual FEV1, predicted 
TLC, 6MWT distance and height. It was statistically 
significant that patients shorter than 160 cm had 
poorer chances of finding a  suitable donor. This 
finding is particularly important among female 
candidates, as a statistically significant difference 
was noted between their percentages in the two 
studied groups. Taller people are also character-
ised by proportionally greater total lung capacity. 
Therefore, height also influenced the aforemen-
tioned parameter, as a  significant difference be-
tween studied groups was distinguished. 
Patients who underwent LTx were on the wait-
ing list for 35 days (on average) less than the de-
ceased ones. Both groups had similar age, weight, 
and body mass index. Laboratory tests revealed 
good functional state of the kidneys and liver 
as well as elevated NT-proBNP level in both the 
groups. Lipid profile and full blood count param-
eters did not differ statistically significantly be-
tween studied groups. 
Pulmonary functional tests, including spirom-
etry, showed reduced parameter values (FEV1% 
and FVC %) among patients who died while on the 
waiting list. The group of patients who underwent 
LTx (FVC%: 50.86, FEV1%: 51.16) showed better 
results than their deceased counterparts (FVC%: 
42, FEV1%: 44.66). A  significant difference was 
observed in actual FEV1 between the two groups. 
Arterial blood gas tests revealed respiratory failure 
in 66.22% of the patients (40.74% of the deceased 
patients, 85% of those who underwent LTx); type 1 
respiratory failure was observed in 43.24% of the 
patients (37.04% of the deceased patients, 60% 
of those who underwent LTx) and type 2 was ob-
served in 22.97% of the patients (22.22% of the de-
ceased patients, 25% of those who underwent LTx). 
Patients who underwent LTx achieved 169 m 
more on average during the 6MWT than their de-
ceased counterparts; this difference was statisti-
cally significant (Table I). Both groups perceived 
exertion approximately at the level of 4 according 
to Borg’s scale. 
Echocardiography revealed normal left ven-
tricle ejection fraction, concurrent with features 
of increased resistance in pulmonary circulation. 
During right heart catheterization, pulmonary 
hypertension was observed in 71.43% of the pa-
tients with IPF (72.73% of the deceased patients 
and 66.67% of those who underwent LTx).
Univariate analysis was performed to deter-
mine which of the parameters were statistically 
significant factors for becoming a  lung recipient. 
Results of the aforementioned analysis are pre-
sented in Table II. Significant factors associated 
with undergoing LTx were as follows: actual FEV1, 
actual TLC, 6MWT distance, height, residual vol-
ume as a percentage of the predicted value, and 
blood type. Patients with blood type AB are ap-
proximately 3 times more likely to become graft 
recipients in comparison to other blood types 
(p = 0.003; 95% CI: 0.009–2.32; HR = 3.32). Tall-
er patients have greater predicted values of FEV
1 
and TLC. Therefore, they will have greater results 
of actual amounts in litres of described parame-
ters in comparison to their shorter counterparts 
presenting the same percentage of these values. 
Risk factors associated with higher probability 
of death while on the LTx waiting list were also 
determined using univariate analysis. Statistically 
significant results are presented in Table III. Pa-
tients with blood type B and those who achieved 
a shorter distance in the 6MWT were more like-
ly to present an unfavourable outcome while 
on the waiting list. Stepwise regression analy-
sis was used to reduce the multivariate model 
to a  single parameter: the 6MWT distance. This 
parameter significantly impacts the probability 
of becoming a  lung recipient (parameter assess-
ment, 0.00523; p = 0.006; 95% CI: 0.0015–0.009; 
Table I. Statistically significant results during qualification for lung transplantation
Parameter All qualified patients 
(n = 84)
Patients deceased 
on waiting list  
(n = 56)
Transplanted  
patients (n = 28)
P-value
Sex, female, % 35 44.64 12.5 0.01b
Height, mean (SD) [cm] 167.54 (9.548) 165.49 (9.874) 172.31 (6.785) 0.004a
Height < 160 cm (%) 23.75 32.14 4.17 0.02b
FEV1 actual, mean (SD) [l] 1.47 (0.659) 1.35 (0.621) 1.78 (0.672) 0.02
a
TLC predicted, mean (SD) [l] 6.07 (1.395) 5.8 (1.410) 7.14 (0.652) 0.03a
6MWT distance, mean (SD) [m] 227.22 (156.452) 176.57 (136.845) 346.24 (135.764) 0.0005a
6MWT – six-minute walk test, FEV
1
 – forced expiratory volume in first second, TLC – total lung capacity. Tests: aMann-Whitney U, bYates’ c2.
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HR = 1.005) as well as that of death while waiting 
for LTx (parameter assessment, –0.0054; p = 0.003; 
95% CI: –0.009 – (–0.0017); HR = 0.995). Due to 
these findings, quantile division of the aforemen-
tioned parameter was performed (1st quantile: 
≤ 72 m, 2nd: 72–252 m, 3rd: 253–350 m, and 4th: 
> 350 m). Further analysis revealed that all qual-
ified patients whose 6MWT distance was within 
the 1st quantile died before LTx. However, the pa-
tients whose 6MWT distances were between the 
2nd and 3rd quantiles had smaller probabilities of 
undergoing LTx (respectively 28.1% and 27.7%) 
than those with 6MWT distances in the 4th quantile. 
The same quantile division was used to assess the 
risk of death while on the LTx waiting list. The anal-
ysis revealed that patients from the 1st quantile had 
10 times greater probability of dying without LTx in 
comparison to those from the 4th quantile. Patients 
from the 3rd quantile were 3 times more likely to 
die than those from the 4th one.
Twenty-eight patients (32.94% of all qualified 
patients) underwent LTx. This group included 23 
(82.14%) men and 5 (17.86%) women. Twenty 
(71.43%) patients underwent SLT and the remain-
ing 8 (28.57%) patients underwent DLT. Mean age 
at the day of LTx was 50.58 years.
Discussion
The IPF is a disease of unknown origin, lead-
ing to complete respiratory insufficiency. It was 
demonstrated by Brown et al. that patients with 
higher BMI, FVC % predicted, FEV
1 % predicted, 
TLC % predicted, and diffusing capacity of lung 
for carbon monoxide % predicted, but a  lower 
FEV
1/FVC ratio and lower mean pulmonary artery 
pressures, had a better chance of reaching 5-year 
survival [12]. This finding is confirmed by Castria 
et al., whose work proved that patients with IPF 
had a  better chance of survival when their pul-
monary artery pressure was low [13]. As a viable 
treatment option, LTx improves lung function in 
patients with IPF. Multivariate analysis showed 
that 6MWT distance is the most significant factor 
influencing the patients’ outcome. However, other 
factors, such as height, blood type and particular 
results of pulmonary function tests, may influence 
the outcome of patients. Our study showed that 
blood type AB was associated with greater proba-
bility of becoming a graft recipient whereas blood 
type O was related to dying while on the waiting 
list. This aspect was also studied by Mackay et al., 
who found that patients with blood type A or B 
Table II. Univariable analysis of factors associated with being transplanted
Parameter Parameter 
assessment
SE c2 test P-value 95% CI HR
Height [cm] 0.10 0.03 12.46 0.0004 0.04–0.15 1.10
FEV1 actual [l] 0.92 0.37 6.35 0.01 0.20–1.64 2.51
Distance [m] 0.01 0.002 8.52 0.004 0.002–0.01 1.01
TLC actual [l] 0.60 0.22 7.28 0.007 0.16–1.03 1.81
RV, % of predicted value 0.03 0.01 6.44 0.01 0.01–0.05 1.03
Blood type O –0.72 0.49 2.16 0.1 –1.67 – 0.24 0.49
Blood type A 0.16 0.44 0.13 0.7 –0.71 – 1.03 1.17
Blood type B 0.02 0.76 0.0004 1.0 –1.47 – 1.50 1.02
Blood type AB 1.20 0.57 4.46 0.03 0.09–2.32 3.32
CI – confidence interval, FEV
1
 – forced expiratory volume in 1st s, HR – hazard ratio, RV – residual volume, TLC – total lung capacity. 
A p-value of < 0.05 is considered statistically significant.
Table III. Univariable analysis of factors associated with death while on the waiting list for lung transplantation
Parameter Parameter 
assessment
SE c2 test P-value 95% CI HR
Distance [m] –0.01 0.001 15.49 0.00008 –0.01 – –0.003 0.99
Blood type O –0.34 0.29 1.37 0.2 –0.91 – 0.23 0.71
Blood type A –0.07 0.29 0.05 0.8 –0.64 – 0.51 0.94
Blood type B 0.95 0.39 5.91 0.02 0.18 – 1.71 2.58
Blood type AB 0.03 0.60 0.003 1.0 –1.15 – 1.21 1.03
CI – confidence interval, HR – hazard ratio. A p-value of < 0.05 is considered statistically significant.
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are more likely to undergo transplantation than 
patients with blood type O [14]. 
In the lung transplantation programme at the 
Silesian Center for Heart Diseases, 102 patients 
with end-stage IPF qualified to undergo LTx be-
tween 2006 and 2017. Eighty-four of these pa-
tients were included in this study, as they had 
reached an end-point (LTx or death while on the 
waiting list). It is worth mentioning that down-siz-
ing of the donor lungs is an important part of do-
nor-recipient matching due to the fibrotic changes 
in the lungs that reduce the thoracic volume of the 
recipient. The average height of men and women 
in Poland is 178.7 cm and 165.1 cm, respectively, 
which implies that taller patients have a greater 
chance of finding a  suitable donor sooner [15]. 
The two studied groups differed significantly in 
terms of height: deceased patients were 165.49 
cm tall on average. Lung recipients were taller, 
with a mean height of 172.31 cm.
A  significant difference was observed in the 
distance achieved during the 6MWT between the 
two studied groups. Patients who underwent LTx 
achieved 346.24 m on average. Deceased patients 
were able to walk less on average (191.21 m). 
A  comparable level of fatigue (according to the 
subjective Borg’s scale) was noted in both groups. 
It is worth mentioning that 6MWT distance has 
been established to be predictive of mortality 
among patients qualified for LTx [10]. This find-
ing was also confirmed by our study, as 6MWT 
was found to have a significant predictive impact 
on the probability of undergoing LTx, as indicat-
ed by Cox proportional hazard analysis. Patients 
who achieved a  6MWT distance between 253 
and 350  m had 3 times greater probability of 
dying while on the waiting list in comparison to 
patients who achieved more than 350 m. Lederer 
et al. published a study indicating that a  low re-
sult obtained in the 6MWT was strongly and inde-
pendently associated with an increased mortality 
rate. Patients with a  walking distance less than 
207 m had a more than fourfold higher mortality 
rate than those with a walking distance of 207 m 
[16]. According to the ISHLT guidelines, in order to 
qualify, patients have to obtain a 6MWT distance 
less than 250  m or show a  decrease of at least 
50 m in this parameter across 6 months [11]. It 
was proved by du Bois et al. that baseline 6MWT 
distance < 250 m was associated with a two-fold 
increase in the risk of mortality and a  24-week 
decline in 6MWT distance > 50 m was associat-
ed with a  nearly three-fold increase in mortality 
risk [17]. It is the authors’ opinion that it is worth 
considering sending patients to begin the qualifi-
cation process sooner, when their 6MWT distance 
is less than 350 m. This might ultimately increase 
their chances of receiving the graft. Taller patients 
are known to achieve longer 6MWT distances. 
Therefore, we took this into consideration but 
did not find that taller patients achieved longer 
6MWT distances. Ikezoe et al. published a  study 
assessing prognostic factors and outcomes of lung 
transplant candidates due to ILD [18]. Their multi-
ple stepwise analysis showed that 6MWT distance 
also independently contributed to mortality of all 
ILD patients. An additional investigation focused 
solely on IPF patients (n = 33) supported by a step-
wise multivariate Cox proportional hazards model 
revealed that BMI and a history of acute exacer-
bation independently contributed to increased 
mortality while waiting for a lung transplantation. 
On the other hand, a study published by Bennett 
et al. presented results contradicting those of 
Ikezoe and ours [19]. Their research demonstrated 
that reduced survival was associated with higher 
levels of partial pressure of carbon dioxide in arte-
rial blood despite average values being within the 
normal range. Finally, Mackay et al. analysed IPF 
mortality among patients awaiting LTx, conclud-
ing that disease progression is a  more sensitive 
indication for LTx referral than any physiological 
measure of disease severity [14]. Lipid profile did 
not differ between the two studied groups, which 
is consistent with the finding that plasma lipid 
levels had a neutral influence on the occurrence of 
the outcomes [20]. Twenty percent of the patients 
receiving lung graft between 2006 and 2017 un-
derwent LTx due to IPF in the Silesian Center for 
Heart Diseases. This makes it the second most 
common group of patients undergoing LTx after 
those undergoing transplantation due to chronic 
obstructive pulmonary disease (30%). The ISHLT 
database shows the following percentages of cas-
es undergoing LTx: chronic obstructive pulmonary 
disease, 36%; IPF, 25% [15]. From the United Net-
work for Organ Sharing registry, which presents 
the comparison of pre-LAS and LAS lung trans-
plant programmes, the conclusion can be drawn 
that LAS is a better system for patients with IPF. 
Before the use of LAS only 15% of patients with 
IPF in the USA underwent LTx, but after implemen-
tation of the LAS system, the percentage of lung 
recipients was 37% [10]. 
In conclusion, the 6-minute walk test distance 
is an independent predictor of mortality on the 
lung transplant waiting list. Patients should be 
referred to lung transplant centres for assess-
ment when their 6-minute walk test distance is 
less than 350 m, which may considerably increase 
their probability of receiving a  lung graft. Blood 
type AB is associated with a  greater chance of 
receiving a graft, whereas blood type O patients 
are more likely to die on the waiting list. Patients’ 
height also plays a  significant role in becoming 
a lung recipient. Due to the small size of the study 
group and its retrospective nature, the authors are 
aware of its limitations. 
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